|
시장보고서
상품코드
2050556
부갑상선 질환 시장 : 유형별, 질환 유형별, 투여 경로별, 연령층별, 성별, 최종사용자별, 유통 채널별, 지역별Parathyroid Disorders Market, By Type, By Disorder Type, By Route of Administration, By Age Group, By Gender, By End User, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
부갑상선 질환 시장은 2026년에 115억 달러로 추정되고 있으며, 2033년까지 146억 2,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 3.5%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 115억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 3.50% | 2033년 시장 규모 예측 : | 146억 2,000만 달러 |
세계의 부갑상선 질환 시장은 최근 부갑상선 질환의 유병률 증가, 진단 기술의 발전, 새로운 치료법 개발로 인해 괄목할 만한 성장을 거듭하고 있습니다. 부갑상선기능항진증과 부갑상선 기능 저하증을 포함한 부갑상선 질환은 부갑상선의 기능 이상을 특징으로 하며, 체내 칼슘과 인산염 농도의 균형을 깨뜨리는 원인이 됩니다. 이러한 질환은 뼈 건강, 심혈관 기능, 그리고 전반적인 삶의 질에 심각한 영향을 미칠 수 있습니다. 부갑상선 질환에 대한 인식이 높아지고 첨단 치료법이 보급됨에 따라 글로벌 부갑상선 질환 시장은 예측 기간 중 상당한 성장을 보일 것으로 예상됩니다.
시장 역학:
세계의 부갑상선 질환 시장은 몇 가지 요인에 의해 주도되고 있습니다. 특히 폐경 후 여성에게 많이 나타나는 원발성 부갑상선기능항진증을 비롯한 부갑상선 질환의 유병률 증가가 대표적입니다. 또한 부갑상선 질환에 취약한 고령 인구의 증가도 시장 성장을 촉진할 것으로 예상됩니다. 영상 진단법의 개선과 유전자 검사 등 진단 기술의 발전으로 부갑상선 질환의 조기 발견과 정확한 진단이 가능해지면서 시장 성장을 더욱 촉진하고 있습니다. 또한 표적치료, 최소침습수술과 같은 새로운 치료법의 개발로 치료의 선택권이 넓어지고 환자들의 예후가 개선되고 있습니다. 그러나 높은 치료 비용, 특정 지역에서의 부갑상선 질환에 대한 낮은 인식, 일부 치료법에 따른 잠재적 부작용 등의 요인으로 인해 시장 성장이 제한될 수 있습니다. 이러한 제약에도 불구하고 부갑상선 질환 분야에서 R&D 활동에 대한 관심 증가, 업계 및 학계와의 협력, 그리고 맞춤형 의료 접근법의 부상으로 인해 부갑상선 질환 분야는 큰 성장 기회가 존재합니다.
본 조사의 주요 특징:
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계의 부갑상선 질환 시장의 주요 기업 개요을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계의 부갑상선 질환 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 부갑상선 질환 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 부갑상선 질환 시장 : 유형별, 2021-2033년
제5장 세계의 부갑상선 질환 시장 : 질환 유형별, 2021-2033년
제6장 세계의 부갑상선 질환 시장 : 투여 경로별, 2021-2033년
제7장 세계의 부갑상선 질환 시장 : 연령층별, 2021-2033년
제8장 세계의 부갑상선 질환 시장 : 성별, 2021-2033년
제9장 세계의 부갑상선 질환 시장 : 최종사용자별, 2021-2033년
제10장 세계의 부갑상선 질환 시장 : 유통 채널별, 2021-2033년
제11장 세계의 부갑상선 질환 시장 : 지역별, 2021-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
KSA 26.06.10Parathyroid Disorders Market is estimated to be valued at USD 11.50 Bn in 2026 and is expected to reach USD 14.62 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 11.50 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.50% | 2033 Value Projection: | USD 14.62 Bn |
The global parathyroid disorders market has witnessed significant growth in recent years, driven by the increasing prevalence of parathyroid disorders, advancements in diagnostic techniques, and the development of novel treatment options. Parathyroid disorders, which include hyperparathyroidism and hypoparathyroidism, are characterized by abnormal functioning of the parathyroid glands, leading to imbalances in calcium and phosphate levels in the body. These disorders can have severe consequences on bone health, cardiovascular function, and overall quality of life. With the rising awareness about parathyroid disorders and the availability of advanced treatment modalities, the global parathyroid disorders market is expected to experience substantial growth during the forecast period.
Market Dynamics:
The global parathyroid disorders market is driven by several factors, including the increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, which is more common in postmenopausal women. Additionally, the growing geriatric population, which is more susceptible to parathyroid disorders, is expected to fuel market growth. Advancements in diagnostic techniques, such as improved imaging modalities and genetic testing, have enabled early detection and accurate diagnosis of parathyroid disorders, further driving market growth. Moreover, the development of novel treatment options, including targeted therapies and minimally invasive surgical procedures, has expanded the treatment landscape and improved patient outcomes. However, the market growth may be restrained by factors such as the high cost of treatments, limited awareness about parathyroid disorders in certain regions, and the potential side effects associated with some treatment options. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing focus on research and development activities, collaborations between industry players and academic institutions, and the emergence of personalized medicine approaches in the field of parathyroid disorders.
Key Features of the Study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global parathyroid disorders market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sandoz (a Novartis division), and Otsuka Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global parathyroid disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global parathyroid disorders market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Drug Class
- Parathyroid Hormone (PTH) Analogues
- Bisphosphonates
- Calcimimetics
- Vitamin D Analogues
- Phosphate Binders
- Diagnostic Method
- Blood Tests
- Imaging Techniques
- Urine Tests
- Disorder Type Insights (Revenue, USD Bn, 2021 - 2033)
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
- Tertiary Hyperparathyroidism
- Hypoparathyroidism
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Outpatient Centers
- Research Institutes
- Diagnostic Centers
- Home Healthcare
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Regeneron Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sandoz (a Novartis division)
- Otsuka Pharmaceutical Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Parathyroid Disorders Market, By Type
- Global Parathyroid Disorders Market, By Disorder Type
- Global Parathyroid Disorders Market, By Route of Administration
- Global Parathyroid Disorders Market, By Age Group
- Global Parathyroid Disorders Market, By Gender
- Global Parathyroid Disorders Market, By End User
- Global Parathyroid Disorders Market, By Distribution Channel
- Global Parathyroid Disorders Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Parathyroid Disorders Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Drug Class
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parathyroid Hormone (PTH) Analogues
- Bisphosphonates
- Calcimimetics
- Vitamin D Analogues
- Phosphate Binders
- Diagnostic Method
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Blood Tests
- Imaging Techniques
- Urine Tests
5. Global Parathyroid Disorders Market, By Disorder Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Primary Hyperparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Secondary Hyperparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Tertiary Hyperparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hypoparathyroidism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Parathyroid Disorders Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Parathyroid Disorders Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Parathyroid Disorders Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Parathyroid Disorders Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Outpatient Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Healthcare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Parathyroid Disorders Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Parathyroid Disorders Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
